EVO — Evotec SE

Summary of Evotec SE Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Group Revenues: EUR 535.1 million for the first nine months, a 7% decline year-over-year.
• D&PD Revenues: Declined by 12% to EUR 391.9 million due to a soft early drug discovery market.
• Just-Evotec Biologics Revenues: Grew by 11% to EUR 143.2 million, driven by a broadening customer base and a significant deal with Sandoz.
• Adjusted EBITDA: Negative EUR 16.9 million, impacted by weaker D&PD revenues.
• Cost Reduction Initiatives: On track to achieve EUR 60 million in structural cost reductions for 2025.
• Free Cash Flow: Improved by 14% year-over-year.

2. Strategic Updates and Business Highlights

• Transformation Strategy: Focus on monetizing technology leadership and enhancing operational capabilities.
• Strategic Partnerships: Continued healthy momentum, with expectations for several molecules to enter Phase II clinical studies in 2026.
• Sandoz Deal: A landmark transaction expected to generate over $650 million in payments, including upfront fees and royalties from biosimilars.
• AI and Technology Platforms: Significant advancements in proprietary platforms, enhancing drug discovery capabilities and reducing time to market.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Confirmed target of EUR 760 million to EUR 800 million.
• Adjusted EBITDA Guidance: Expected in the range of EUR 30 million to EUR 50 million.
• Mid-Term Outlook: Anticipated top-line growth of 8% to 12% and EBITDA margins exceeding 20% by 2028.

4. Bad News, Challenges, or Points of Concern

• Market Headwinds: Continued softness in the early drug discovery market, with VC funding for biotech remaining below pre-pandemic levels.
• D&PD Business Challenges: The decline in revenue and profitability due to a cautious spending environment among biotech clients.
• Negative Change Orders: Although normalizing, they previously impacted sales performance significantly.
• Visibility Issues: Limited visibility into 2026 revenue growth, with cautious expectations for market recovery.

5. Notable Q&A Insights

• Sandoz Revenue Contribution: Non-Sandoz revenues accounted for over 50% of total year-to-date revenues, with the Toulouse site build-out costing around EUR 20 million.
• Revenue Trajectory: Expected revenue growth for 2026 is uncertain, with a cautious stance on predicting a 5% growth rate.
• Pricing Environment: The pricing landscape is adjusting due to overcapacity in the market, but normalization is anticipated as demand stabilizes.
• Geographic Performance Variability: Mixed performance across regions, with a recent shift favoring the European market over the U.S. market.

This summary encapsulates the key points from Evotec's Q3 2025 earnings call, highlighting both the company's achievements and the challenges it faces moving forward.